2024 — A large-scale clinical trial of treatment strategies for Crohn's disease has shown that offering early advanced therapy to all patients straight after diagnosis can drastically improve ...

Children with Crohn’s disease are at higher risk of developing perianal fistulas ... These deleterious effects often occur in children and are difficult to treat. Therefore, early treatment or ...

Remestemcel-L is under clinical development by Mesoblast and currently in Phase III for Crohn's Disease (Regional Enteritis).

A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease, a new ...

Early treatment of pediatric Crohn's disease with anti-tumor necrosis factor medications can substantially reduce the risk of ...

The FDA has approved Steqeyma® (ustekinumab-stba), a biosimilar to Stelara®, for the treatment of various chronic ...

Steqeyma is approved for adult and pediatric patients with plaque psoriasis and active psoriatic arthritis as well as adults ...

Infliximab biosimilar is under clinical development by Celltrion and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Ustekinumab-stba, manufactured by Celltrion, is expected to be marketed in the United States in February 2025.